- Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs
- Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates
- Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology
- Triggers $5 million immediate payment to Synaffix and total potential payments for the first ADC program alone of up to $171m plus royalties on commercial sales
